

Technetium-99m-Tetrofosmin SPECT Imaging of Lung Lesions: A Not-So-Negative Study

TO THE EDITOR: We read with great interest the article by Kao et al. (1) on the use of ^{99m}Tc -tetrofosmin SPECT imaging in the evaluation of single solid lung masses, based on the findings of chest radiographs. They evaluated 49 patients, 41 with malignant lung lesions and 8 with benign ones, and reported a diagnostic sensitivity, specificity and accuracy of 61%, 50% and 59%, respectively. On the basis of these results, the authors state that ^{99m}Tc -tetrofosmin SPECT of the chest is of little or no value for differentiating malignant from benign lung lesions and for the detection of cancer when diagnosing single solid lung masses.

The clinical usefulness of ^{99m}Tc -tetrofosmin as a tumor-seeking agent in lung cancer is currently under investigation in several institutions, mirroring previous experiences with ^{201}Tl and ^{99m}Tc -sestamibi. As cited in the study of Kao et al. (1), we reported on the use of ^{99m}Tc -tetrofosmin SPECT in patients with radiological evidence of lung lesions (2), obtaining a sensitivity of 95% (18/19) for the detection of primary lung cancer and a specificity of 100% (no pathological accumulation of the radiopharmaceutical was observed in the 6 patients with benign lesions). On the basis of these preliminary but encouraging findings, we investigated the role of ^{99m}Tc -tetrofosmin SPECT in a larger series of patients with lung lesions to better evaluate its diagnostic accuracy. To date we have studied a total of 67 patients, 46 with malignancies and 21 with benign lung lesions; sensitivity, specificity and accuracy of ^{99m}Tc -tetrofosmin imaging in the detection of lung cancer have been 93%, 86% and 91%, respectively (unpublished data). These results are similar to those reported by other authors both for sensitivity and specificity (3–5); nevertheless other studies yielded a comparable high sensitivity but a lower specificity (6,7).

In contrast with these findings, the sensitivity found by Kao et al. (1) is quite low compared with that obtained in other studies using ^{99m}Tc -sestamibi. In fact, only their previous article (8) reports a low sensitivity (65%), whereas sensitivities obtained in the works of Hassan et al. (9) and Lebouhiller et al. (10), which were cited by Kao et al. (1), are clearly higher (91% and 96%, respectively). Although we agree with the conclusion of Kao et al. (1) that a different P-glycoprotein expression may explain this discrepancy, in our opinion, tumor size is also important for detection. Their results show that sensitivity is 74% (17/23) for cancers >4 cm and only 44% (8/18) for those ≤4 cm.

With regard to specificity, the small number of benign lesions in the study by Kao et al. (1) has to be taken into account when considering their findings. Moreover, the intrathoracic goiter (Patient no. 45), which demonstrated positive ^{99m}Tc -tetrofosmin uptake, must not be considered to be a solid lung mass; in fact, a chest CT would have simply clarified its nature.

In conclusion, we think that the negative conclusions of Kao et al. (1) regarding the usefulness of ^{99m}Tc -tetrofosmin SPECT imaging in patients with lung lesions are premature. The results of various studies (2–7) indicate that this radiopharmaceutical is highly sensitive in the detection of lung cancer. Because of the small total number of patients with benign lesions considered, larger series are required to finally determine the clinical role of ^{99m}Tc -tetrofosmin imaging in differentiating malignant from benign lung lesions and its specificity.

REFERENCES

1. Kao CH, ChangLai SP, Shen YY, Lee JK, Wang SJ. Technetium-99m-tetrofosmin SPECT imaging of lung masses: a negative study. *J Nucl Med* 1997;38:1015–1019.
2. Schillaci O, Volpino P, Tavolaro R, et al. Detection of primary lung cancer with technetium-99m-tetrofosmin [Abstract]. *J Nucl Med* 1996;37(suppl):35P–36P.
3. Yurekli Y, Eray T, Sayit E, et al. Technetium-99m-tetrofosmin SPECT in lung cancers: a comparative study with thallium-201 [Abstract]. *Eur J Nucl Med* 1995;22:832.
4. Tulus A, Nardali M, Gulmez G, Silov G, Kibar M, Karahagioglu E. Evaluation of primary lung cancer with Tc-99m-tetrofosmin in comparison to Tc-99m MIBI uptake [Abstract]. *Eur J Nucl Med* 1996;22:1212.

5. Spanu A, Ginesu F, Dettori G, et al. Tc-99m-tetrofosmin scan in lung and breast cancer detection uptake [Abstract]. *Eur J Nucl Med* 1996;22:1213.
6. Atasaver T, Gokcora N, Vural G, Cetin N, Ozturk C, Unlu M. Evaluation of malignant and benign lung lesions with ^{99m}Tc -tetrofosmin. *Nucl Med Commun* 1996;17:577–582.
7. Basoglu T, Coskun C, Bernay I, Sahin M, Talu A, Erkan L. Evaluation of Tc-99m-tetrofosmin uptake in benign and malignant lung lesions [Abstract]. *Eur J Nucl Med* 1996;22:1212.
8. Kao CH, Wang SJ, Lin WJ, Hsu CY, Liao SQ, Yeh SH. Differentiation of single solid lesions in the lungs by means of single-photon emission tomography with technetium-99m methoxy-isobutylisonitrile. *Eur J Nucl Med* 1993;20:249–254.
9. Hassan IM, Sahweil A, Constantinides C, et al. Uptake and kinetics of Tc-99m hexakis 2-methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. *Clin Nucl Med* 1989;14:333–340.
10. Lebouhiller G, Taillefer R, Lambert R, et al. Detection of primary lung cancer with ^{99m}Tc -sestamibi [Abstract]. *J Nucl Med* 1993;34(suppl):140P.

Orazio Schillaci

*Nuclear Medicine
University of L'Aquila
Rome, Italy*

Valentina Picardi

Francesco Scopinaro
*Section of Nuclear Medicine
University "La Sapienza"
Rome, Italy*

Technetium-99m-Tetrofosmin Scintigraphy, P-Glycoprotein and Lung Cancer

TO THE EDITOR: We read with interest the article by Kao et al. (1) that referred to the study of lung masses by means of SPECT imaging of the chest using ^{99m}Tc -tetrofosmin (TF). They evaluated ^{99m}Tc -TF for its ability to differentiate between malignant and benign lesions in single solid lung masses. They conclude by saying that, " ^{99m}Tc -TF SPECT of the chest is of little or no value for the detection of lung cancer from single solid lung masses." We would like to express some additional considerations concerning the kinetics and uptake of this radiopharmaceutical in lung cancer and communicate our experience.

In vitro studies involving cultured tumor cell lines, uptake of ^{99m}Tc -TF and ^{99m}Tc -hexakis-isobutyl isonitrile-2-methoxyisobutyl isonitrile (MIBI) has been shown to be rapid during the first few minutes, after which time it continues to increase gradually during the first hour of incubation, at which time it reaches a plateau of at least 4 hr duration (2). Thus, the assessment of in vivo studies should not be based exclusively on early images (15–30 min). A later acquisition would also allow clearance of the circulating vascular background. Kao et al. (1) assessed a single study performed 15–30 min postinjection, which may have influenced their findings.

They mention the possible mechanisms of ^{99m}Tc -TF uptake by tumor cells (1). These mechanisms, like those of ^{99m}Tc -MIBI, are related to the number of mitochondria in the cells. Thus, uptake is observed in those tissues whose cells present elevated energy requirements, whether they be tumor cells, inflammatory cells or cells of some other type (which explains their use in myocardial perfusion). Kao et al. (1) observed uptake by 4 of 8 benign lesions corresponding to granulation tissue, mucormycosis, fungal abscess and intrathoracic goiter. In a preliminary study involving the use of ^{99m}Tc -TF in 5 patients with lung cancer (3), we also observed a false-positive result in the mediastinum that was caused by tuberculous lymphadenitis. The key to differentiating between malignant and benign lesions probably lies in the analysis of the amount of radiopharmaceutical deposited in the target tissue with respect to healthy tissue (tumor-to-healthy tissue ratio). This semiquantitative analysis has already proved its utility in other studies involving ^{99m}Tc -MIBI (4).